TOTAL: $273.44M

Company (Symbol)

Type Of Financing

Number Of Shares, Units Or Warrants (M)

Amount Raised ($M)

Investors; Placement Agents; Details (Date)@

Affymetrix Inc. (AFFX)

Private placement of convertible subordinated notes

­

$150

Affymetrix completed the private placement of $125M principal amount of 5% convertible subordinated notes with an undisclosed entity that exercised its option to purchase an additional $25M of notes for gross proceeds of $150M; the notes are convertible, subject to adjustment under certain circumstances, into Affymetrix common stock at a price equal to $123 per share (9/17)

Avant Immunotherapeutics Inc.

Private placement of common stock

5.5S

$10.5

Avant closed a private placement of 5.5M shares of common stock at $1.92 per share; Nomura International plc acted as placement agent (9/22)

Boston Life Sciences Inc. (BLSI)

Private placement of convertible debentures

­

$8

Boston Life completed a private placement of $8M in convertible debentures with a single institutional investor; H.C. Wainwright & Co. acted as placement agent (9/22)

Cephalon Inc. (CEPH)

Private placement of convertible exchangeable preferred stock

0.5S

$25

The initial purchasers of Cephalon's previously announced offering of 2M shares of convertible exchangeable preferred stock at $50 per share exercised in full their overallotment option to purchase an additional 0.5M shares at $50 per share; shares of the preferred stock are convertible at a rate of $17.92 per share, and are redeemable at the option of the company in two years; exercise of the overallotment option brings the total amount of the original offering to $125M (9/27)

CuraGen Corp. (CRGN)

Private placement of common stock

1.5S

$15

CuraGen completed a private placement of 1.5M shares of common stock at $10 per share to funds managed by Pequot Capital Management Inc. (9/8)

Guilford Pharmaceuticals Inc. (GLFD)

Private placement of common stock

3.4S

$45

Guilford completed the sale of an aggregate of 3.4M newly issued shares of common stock to institutional and other accredited investors at $13.50 per share; Prudential Vector Healthcare Group, a unit of Prudential Securities Inc., served as placement agent (9/24)

InKine Pharmaceutical Inc. (INKP)

Private placement of common stock and warrant

2.3S and 1W

$3

InKine secured $3M in a private placement consisting of 2.3M new shares of common stock and a four-year warrant for 0.8M additional shares at a strike price of $1.78; participants included placement agent Ladenburg Thalmann & Co. Inc., the Tail Wind Fund Ltd, of London, and Oxford Bioscience Partners, InKine's largest shareholder (9/21)

Precision Biochemicals Inc. (a subsidiary of Pharma Inc.; company (9/9) Canada; TSE:IGT)

Private placement of equity in exchange for a 40% equity position in the company (9/9)

­

C$0.5 US$0.34

The Biopharmaceutical Innovation Resource Fund invested C$0.5M (US$0.34) in Precision

SuperGen Inc.

Private placement transaction

ND

$16.6

SuperGen closed a private placement transaction with Capital Research & Management Co.; further details ND (9/7)